ArticleProbiotics and antimicrobial proteins2026
Discovery and Characterization of a Novel Bacteriocin PFS-3 Targeting Multidrug-Resistant Escherichia coli.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The widespread use of commercial antibiotics has led to the emergence of multidrug resistance in pathogenic bacteria, posing a significant threat to human health and underscoring the urgent need for alternative antimicrobial agents. In this study, a bacteriocin-producing strain, Bacillus velezensis FS-3 (B. velezensis FS-3), was isolated from soil in Changbaishan, China. Fermentation conditions were optimized to enhance both bacteriocin activity and yield. A novel bacteriocin, PFS-3, was purified from B. velezensis FS-3 using hydrochloric acid precipitation, organic solvent extraction, and preparative reversed-phase high-performance liquid chromatography. Liquid chromatography-mass spectrometry/mass spectrometry analysis determined its molecular weight to be 929.16 Da, and amino acid sequencing of this peptide revealed eight amino acids (STYLFEGL). To date, the biological properties of PFS-3 have not been reported. We demonstrate here that PFS-3 exhibits low toxicity and remarkable stability under diverse conditions, including variations in temperature, pH, and the presence of metal ions or organic reagents. PFS-3 displayed broad-spectrum antimicrobial activity, with particularly strong activity against Gram-negative bacteria. Notably, its minimum inhibitory concentration against multidrug-resistant Escherichia coli B2 (MDR E. coli B2) was 16 μg/mL. Mechanistic investigations revealed that bacteriocin PFS-3 exerts bactericidal effects on MDR E. coli B2 by disrupting cardiolipin in the outer membrane of the cells. Furthermore, in vivo experiments demonstrated that PFS-3 significantly improved survival rates in infection models of MDR E. coli. In conclusion, PFS-3 is a newly identified bacteriocin with strong antibacterial activity, high stability, safety, and a favorable therapeutic index, highlighting its potential applications in the food industry and biopharmaceuticals for combating MDR E. coli infections.
Indexed as
Identifiers
41339617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.